Published in World J Gastroenterol on May 21, 2014
Hepatitis B virus (HBV) receptors: Deficiency in tumor results in scant HBV infection and overexpression in peritumor leads to higher recurrence risk. Oncotarget (2015) 0.81
Capture and Identification of Heterogeneous Circulating Tumor Cells Using Transparent Nanomaterials and Quantum Dots-Based Multiplexed Imaging. J Cancer (2016) 0.78
Prognostic value of circulating tumor cells in the peripheral blood of patients with esophageal squamous cell carcinoma. Onco Targets Ther (2017) 0.75
Diosmetin inhibits cell proliferation and induces apoptosis by regulating autophagy via the mammalian target of rapamycin pathway in hepatocellular carcinoma HepG2 cells. Oncol Lett (2016) 0.75
Lactoferrin-modified PEGylated liposomes loaded with doxorubicin for targeting delivery to hepatocellular carcinoma. Int J Nanomedicine (2015) 0.75
A hybrid substratum for primary hepatocyte culture that enhances hepatic functionality with low serum dependency. Int J Nanomedicine (2015) 0.75
Prognostic Value of Serum Caspase-Cleaved Cytokeratin-18 Levels before Liver Transplantation for One-Year Survival of Patients with Hepatocellular Carcinoma. Int J Mol Sci (2016) 0.75
The diagnostic value of assays for circulating tumor cells in hepatocellular carcinoma: A meta-analysis. Medicine (Baltimore) (2017) 0.75
Anti-exudation effects of sodium ferulate and oxymatrine combination via modulation of aquaporin 1. Exp Ther Med (2017) 0.75
Use digital subtraction images of blue-light and near-infrared autofluorescence for the assessment of irregular foveal contour. Lasers Med Sci (2014) 0.75
Global cancer statistics. CA Cancer J Clin (2011) 185.92
The basics of epithelial-mesenchymal transition. J Clin Invest (2009) 32.82
Circulating tumor cells, disease progression, and survival in metastatic breast cancer. N Engl J Med (2004) 27.92
Circulating tumor cells predict survival benefit from treatment in metastatic castration-resistant prostate cancer. Clin Cancer Res (2008) 14.37
A perspective on cancer cell metastasis. Science (2011) 13.31
Epidemiology of viral hepatitis and hepatocellular carcinoma. Gastroenterology (2012) 10.00
Relationship of circulating tumor cells to tumor response, progression-free survival, and overall survival in patients with metastatic colorectal cancer. J Clin Oncol (2008) 8.72
The role of surface carbohydrates in the hepatic recognition and transport of circulating glycoproteins. Adv Enzymol Relat Areas Mol Biol (1974) 7.83
EpCAM-positive hepatocellular carcinoma cells are tumor-initiating cells with stem/progenitor cell features. Gastroenterology (2008) 5.53
EpCAM and alpha-fetoprotein expression defines novel prognostic subtypes of hepatocellular carcinoma. Cancer Res (2008) 4.17
Clinical significance and molecular characteristics of circulating tumor cells and circulating tumor microemboli in patients with small-cell lung cancer. J Clin Oncol (2012) 3.51
Glypican-3: a novel serum and histochemical marker for hepatocellular carcinoma. Gastroenterology (2003) 2.90
Detection and HER2 expression of circulating tumor cells: prospective monitoring in breast cancer patients treated in the neoadjuvant GeparQuattro trial. Clin Cancer Res (2010) 2.66
Acquired expression of periostin by human breast cancers promotes tumor angiogenesis through up-regulation of vascular endothelial growth factor receptor 2 expression. Mol Cell Biol (2004) 2.49
Epithelial cell adhesion molecule (Ep-CAM) modulates cell-cell interactions mediated by classic cadherins. J Cell Biol (1997) 2.27
Recurrence after liver resection for hepatocellular carcinoma: risk factors, treatment, and outcomes. Surgery (2006) 2.24
The asialoglycoprotein receptor: relationships between structure, function, and expression. Physiol Rev (1995) 2.07
Intermediate-sized filaments of human endothelial cells. J Cell Biol (1979) 2.06
Circulating stem cell-like epithelial cell adhesion molecule-positive tumor cells indicate poor prognosis of hepatocellular carcinoma after curative resection. Hepatology (2013) 1.84
The asialoglycoprotein receptor: a model for endocytic transport receptors. Biochemistry (1990) 1.78
HER2-positive circulating tumor cells in breast cancer. PLoS One (2011) 1.73
The US Food and Drug Administration perspective on cancer biomarker development. Nat Rev Cancer (2006) 1.67
Usefulness of alpha-fetoprotein in the diagnosis of hepatocellular carcinoma. Anticancer Res (2003) 1.55
Impact of cytomorphological detection of circulating tumor cells in patients with liver cancer. Hepatology (2004) 1.48
Enhanced glypican-3 expression differentiates the majority of hepatocellular carcinomas from benign hepatic disorders. Gut (2001) 1.46
Present and future possibilities for early diagnosis of hepatocellular carcinoma. World J Gastroenterol (2010) 1.40
EpCAM, a new marker for cancer stem cells in hepatocellular carcinoma. J Hepatol (2009) 1.33
Detection of circulating cytokeratin-positive cells in the blood of breast cancer patients using immunomagnetic enrichment and digital microscopy. Clin Cancer Res (2002) 1.33
Correlation analysis of preoperative serum alpha-fetoprotein (AFP) level and prognosis of hepatocellular carcinoma (HCC) after hepatectomy. World J Surg Oncol (2013) 1.22
Beta-catenin expression is altered in human colonic aberrant crypt foci. Cancer Res (2001) 1.17
Isolation of circulating tumor cells in patients with hepatocellular carcinoma using a novel cell separation strategy. Clin Cancer Res (2011) 1.14
Circulating endothelial cells: a novel marker of endothelial damage. Clin Chim Acta (2006) 1.13
A membrane receptor protein for asialoglycoproteins. Methods Enzymol (1974) 1.11
The asialoglycoprotein receptor mediates hepatic binding and uptake of natural hepatitis B virus particles derived from viraemic carriers. J Gen Virol (1994) 1.09
Diagnostic value of glypican-3 in serum and liver for primary hepatocellular carcinoma. World J Gastroenterol (2010) 1.08
Quantitative proteomic signature of liver cancer cells: tissue transglutaminase 2 could be a novel protein candidate of human hepatocellular carcinoma. J Proteome Res (2008) 1.07
A novel function for vimentin: the potential biomarker for predicting melanoma hematogenous metastasis. J Exp Clin Cancer Res (2010) 1.06
Glypican-3 as a potential differential diagnosis marker for hepatocellular carcinoma: a tissue microarray-based study. Acta Histochem (2011) 1.01
Cytokeratin 8/18 as a new marker of mouse liver preneoplastic lesions. Toxicol Appl Pharmacol (2009) 0.91
The human asialoglycoprotein receptor is a possible binding site for low-density lipoproteins and chylomicron remnants. Biochem J (1991) 0.89
Circulating tumor cells are associated with diffuse spread in stage IV colorectal cancer patients. Cancer Biol Ther (2013) 0.88
Cancer stem cell characteristics of circulating tumor cells. Int J Radiat Biol (2014) 0.88
Assessment of alpha-fetoprotein in the diagnosis of hepatocellular carcinoma in Middle Eastern patients. Dig Dis Sci (2010) 0.88
CD133, Stem Cells, and Cancer Stem Cells: Myth or Reality? Curr Colorectal Cancer Rep (2011) 0.88
Expression of keratin 19 is related to high recurrence of hepatocellular carcinoma after radiofrequency ablation. Oncology (2011) 0.87
Antisense oligonucleotides targeted against asialoglycoprotein receptor 1 block human hepatitis B virus replication. J Viral Hepat (2006) 0.86
Dickkopf-1: as a diagnostic and prognostic serum marker for early hepatocellular carcinoma. Int J Biol Markers (2013) 0.83
Asialoglycoprotein receptor interacts with the preS1 domain of hepatitis B virus in vivo and in vitro. Arch Virol (2011) 0.81
Fibronectin and asialoglyprotein receptor mediate hepatitis B surface antigen binding to the cell surface. Arch Virol (2010) 0.81
Prognotic impact of serum follistatin in patients with hepatocellular carcinoma. J Gastroenterol Hepatol (2013) 0.78